Company:  VICAL INC (VICL)
Form Type:  8-K
Filing Date:  2/12/2014 
CIK:  0000819050 
Address:  10390 PACIFIC CENTER COURT
.
 
City, State, Zip:  SAN DIEGO, California 92121-4340 
Telephone:  858-646-1100 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$4.03  
Change: 
-0.35 (-7.99%)  
Trade Time: 
Jul 22  
Market Cap: 
$37.08M
Trade VICL now with 

© 2016  
Description of Business
We research and develop biopharmaceutical products, including those based on our patented DNA delivery technologies, for the prevention and treatment of serious or life-threatening diseases. We currently have four active, independent or partnered, development programs in the area of infectious disease comprised of: · An ongoing Phase 3 clinical trial of ASP0113 for prevention of cytomegalovirus, or CMV, reactivation in hematopoietic stem cell transplant recipients and an ongoing Phase 2 clinical trial of ASP0113 for prevention of CMV infection in kidney transplant recipients, both in collaboration with Astellas Pharma Inc., or Astellas. Astellas expects enrollment in the Phase 3 clinical trial to be completed during the third quarter of 2016.
Register and access this filing in:     
  FORM 8-K
    SECTION 2 FINANCIAL INFORMATION
      Item 2.02. Results of Operations and Financial Condition.
    SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
      Item 9.01. Financial Statements and Exhibits.
    SIGNATURES
    INDEX TO EXHIBITS
  EXHIBIT 99
    INCOME STATEMENT